News Search Results
Nov 03, 2025, 08:08 ET Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025
3-5 hemorrhage occurred in 2% of LENVIMA-treated patients, including 1 fatal intracranial hemorrhage among 16 patients who received LENVIMA and had CNS metastases at baseline. In RCC, grade 3-5 hemorrhage occurred in 8% of LENVIMA + everolimus–treated patients, including 1 fatal cerebral hemorrhage.
More news about: Eisai Inc.
Nov 03, 2025, 08:00 ET Servier Announces Positive Findings from Longer-Term Analysis of the Phase 3 INDIGO Trial Showing Continued Durable Treatment Effect of VORANIGO® (vorasidenib) Published in The Lancet Oncology
Astrocytoma, IDH-mutant (CNS WHO grades 2-4) Oligodendroglioma, IDH-mutant and1p19q-codeleted (CNS WHO grades 2-3) Glioblastoma, IDH-wildtype (CNS WHO grade 4)
More news about: Servier Pharmaceuticals
Nov 03, 2025, 08:00 ET Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Likelihood of may
More news about: Indivior PLC
Oct 31, 2025, 11:50 ET The Galien Foundation Honors Michael J. Fox and 2025 Prix Galien Award Recipients
Jamey EDWARDSFormer CEO, Emergent Medical Associates Amir KALALIM.D., Chairman & Chief Curator CNS Summit/Co-Chair Decentralized Trial Research Alliance Michelle LONGMIREM.D., Co-Founder & CEO, Medable
More news about: The Galien Foundation
Oct 31, 2025, 09:00 ET Zhimeng Biopharma's investigational drug CB03-154 for amyotrophic lateral sclerosis has achieved the first patient first dose milestone in the phase 2/3 pivotal clinical trial.
dedicated to develop small-molecule drug discovery with focused on the functional cure of chronic hepatitis B (CHB), as well as novel therapies for CNS disorders, including epilepsy, neuropathic pain (e.g. cancer-related pain), amyotrophic lateral sclerosis (ALS), major depressive disorder (MDD), and
More news about: Shanghai Zhimeng Biopharma Inc.
Oct 31, 2025, 08:00 ET Servier's VORANIGO® (vorasidenib) Receives Prestigious 2025 Prix Galien USA Award
1 Gliomas are tumors that arise from glial or precursor cells within the central nervous system (CNS). The 2021 World Health Organization (WHO) classification recognizes four general groups of gliomas, one of which is adult-type diffuse gliomas. These
More news about: Servier Pharmaceuticals
Oct 30, 2025, 17:31 ET Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
The atypical teratoid/rhabdoid tumor market growth is driven by rising molecular diagnosis and increased awareness of this aggressive pediatric CNS cancer, which is expanding the pool of identified patients. Additionally, the launch of emerging therapies such as PD-1 inhibitor (Nivolumab), Aurora
More news about: DelveInsight Business Research, LLP
Oct 30, 2025, 16:22 ET Cohen & Steers, Inc. Declares Quarterly Dividend
NEW YORK, Oct. 30, 2025 /PRNewswire/ -- The Board of Directors of Cohen & Steers, Inc. (NYSE: CNS) declared a cash dividend for the fourth quarter of 2025 in the amount of $0.62 per share of common stock payable on November 20, 2025, to stockholders
More news about: Cohen & Steers, Inc.
Oct 30, 2025, 09:00 ET Signant Health Appoints Internationally Recognized Cognitive Assessment Expert John Harrison to Further Advance Innovation in CNS Clinical Trials
Harrison. "I'm excited to join Signant at this pivotal time and work alongside the team to advance how we measure and interpret cognitive outcomes in CNS trials. Signant's commitment to scientific rigor and its deep therapeutic expertise make it the ideal partner for sponsors developing the next generation
More news about: Signant Health
Oct 30, 2025, 07:00 ET NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
central nervous system and neurodegenerative disorders, and Aexon Labs, a biotechnology company advancing next-generation central nervous system ("CNS") therapeutics, today announced the expansion of their DOXA platform with the AEX-6xx series, a new generation of small molecules targeting arousal stability,
More news about: NLS Pharmaceutics Ltd.
Oct 30, 2025, 06:30 ET Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2025 Financial Results
intracranial regression at their clinically relevant doses. Additionally, NVL-330 induced intracranial tumor regression in mice that had progressed in the CNS on zongertinib. These data add to the preclinical characterization of NVL-330 as a brain penetrant TKI that is broadly active against HER2 oncogenic
More news about: Nuvalent, Inc.
Oct 29, 2025, 09:55 ET Connected Nation highlights Cybersecurity Awareness Month with intergenerational internet safety event in Dallas
adults and older adults gain the skills to use technology safely, confidently and meaningfully." The Dallas event underscored CN's commitment to advancing digital safety, inclusion, and empowerment nationwide. Through Teens Teach Tech, powered by AT&T, more than 150 youth teams
More news about: Connected Nation
Oct 29, 2025, 08:30 ET Miami Biotech Collective Introduces Board of Advisors and Women's Leadership Council to Shape South Florida's Biotech Future
CNS2, is an entrepreneur and life sciences innovator, recognized among the Top 10 Inspirational Women in Nordic Life Science (2023) and Endpoints 20 Under
More news about: Miami Biotech Collective
Oct 28, 2025, 17:07 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Oct 28, 2025, 17:00 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Oct 28, 2025, 17:00 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Oct 28, 2025, 16:53 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Oct 28, 2025, 16:51 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Oct 28, 2025, 11:56 ET New SK Life Science, Inc. Survey Reveals Communication Gaps Between Patients and Providers That Can Impact Epilepsy Care Outcomes
SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., reveal striking communication gaps between patients and providers that can stand in the
More news about: SK Life Science, Inc.
Oct 28, 2025, 09:15 ET AI Set to Transform Pediatric Neuro-Oncology: A New Era in Treatment and Assessment
equitable access so that AI tools are safe, effective, and trustworthy at the point of care. Pediatric central nervous system (CNS) tumors are the most common solid tumors in children and adolescents, with approximately 48,000 new cases annually worldwide. Prognosis varies due to
More news about: Children's Hospital of Philadelphia
Oct 28, 2025, 07:00 ET Corero Network Security Solves Encrypted DDoS Blind Spot for Service Providers and Enterprises
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, today announced a new
More news about: Corero Network Security
Oct 27, 2025, 03:56 ET Cipla's flagship respiratory initiative Breathefree broadens its footprint in the UAE
Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms
More news about: Cipla
Oct 24, 2025, 09:54 ET SK Life Science, Inc. to Host "Illuminating the Path to Added Seizure Reduction" Symposium at the 2025 American Epilepsy Society Annual Meeting
SK Life Science, Inc., a global leader in treatments for central nervous system (CNS) disorders and a subsidiary of SK Biopharmaceuticals Co., Ltd., today announced it will host an educational symposium led by world-renowned epileptologists
More news about: SK Life Science, Inc.
Oct 23, 2025, 09:21 ET METiS BioTech announces China's First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial
symptom-free days and sustained improvement throughout the 12-week treatment period. MTS-004 achieved statistically significant improvements over placebo in: CNS-LS (Center for Neurologic Study–Lability Scale) total score, CGI-C (Clinical Global Impression of Change) and PGI-C (Patient Global Impression of Change),
More news about: METiS TechBio
Oct 23, 2025, 08:33 ET BridGene Biosciences to Present Three Posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
including GPCRs, phosphatases, and kinases. In GPCR studies, BGP-1951 inhibited serotonin-induced calcium influx through 5-HT₂A while avoiding common CNS toxicity profiles, and BGP-2992 acted as a positive allosteric modulator of CXCR4 signaling with therapeutic potential in neuroinflammation. Among phosphatases,
More news about: BridGene Biosciences